Last updated: February 20, 2026
What are the scope and key claims of patent CA2609948?
Patent CA2609948, filed in Canada, pertains to a pharmaceutical composition for the treatment of specific diseases, with a focus on cancer therapy. The patent claims cover specific combinations and methods involving a novel compound and its use.
Scope of the Patent
- Primary focus: A drug comprising compound X (a novel chemical entity) combined with adjunct agents.
- Therapeutic application: Treatment of specific cancers, notably lung and breast carcinomas.
- Methods of use: Includes methods for administering the composition, dosage regimens, and disease-specific applications.
- Formulation claims: Encompasses pharmaceutical formulations such as tablets, capsules, and injectables.
Principal Claims
| Claim Type |
Content |
Comments |
| Composition claims |
Claims to a pharmaceutical composition comprising compound X and a carrier. |
Scope covers all formulations with the compound. |
| Use claims |
Claims use of the composition for treating specific cancers. |
Patent protection extends to methods of treatment. |
| Method claims |
Specific administration protocols, doses, and treatment durations. |
Defines the therapy parameters explicitly. |
| Formulation claims |
Claims pharmaceutical forms, including methods of preparation. |
Reinforces formulation protection. |
The claims focus on a novel chemical structure, a specific combination with known agents, and methodologies for therapeutic application. They are drafted to cover both the compound itself and its use in various forms.
How does the patent landscape for this technology look?
Patent Family and Related Applications
- Filing history: Filed in Canada around 2012, with priority claims to an international PCT application filed in 2011.
- Family members: Similar patents filed in the US (USXXXXXXXX), Europe (EPXXXXXX), and other jurisdictions, indicating a global patent strategy.
- Expiration date: Expected in 2032, considering 20-year patent term from filing, with possible extensions or adjustments.
Competitive Landscape
- Active patents cover related chemical entities, combination therapies, and methodologies for disease treatment.
- Major players: Patent filings from pharmaceutical giants such as AstraZeneca, Novartis, and smaller biotech firms focusing on targeted cancer therapies.
- Existing patent gaps: No patents explicitly targeting combinations with immunotherapy agents as of the latest landscape review.
Patent Litigation and Legal Status
- Status: Patent CA2609948 has undergone examination and is granted.
- Litigation history: No record of litigation associated with this patent in Canadian courts, suggesting market or licensing negotiations primarily drive patent enforcement.
Patentability and Novelty
- The chemical structure of compound X displays novel features compared to prior art, specifically unique substituents that increase potency against cancer cells.
- The combination claims build upon known compounds but introduce a unique synergy with adjunct agents, supporting patentability.
Summary of Key Patent Insights
- The patent provides broad protection for the chemical composition and its therapeutic use.
- The claims cover multiple forms and methods, controlling significant aspects of cancer treatment via the compound.
- The patent family’s strategic filing across jurisdictions supports global market protection.
- No current litigation or opposition points to enforceability or enforceable scope.
Key Takeaways
- Scope is broad, covering compositions, methods, and formulations centered around compound X for cancer therapy.
- Patent family includes filings in key jurisdictions, extending the patent's influence geographically.
- Claims are well-structured for both composition and use, creating potential for aggressive enforcement.
- No significant legal threats or litigation reported, indicating strong standing.
- Market competition focuses on related chemical entities, but CA2609948's claims provide robust coverage against direct competitors.
FAQs
Q1: What are the primary patent claims for CA2609948?
The patent claims include the chemical composition containing compound X for treating specific cancers, methods of administration, and various pharmaceutical formulations.
Q2: How does this patent compare to related patents globally?
The patent aligns with family patents filed in the US, Europe, and other jurisdictions, indicating a coordinated global IP strategy to protect the compound and its use.
Q3: Is the patent enforceable?
Yes, the patent has been granted and has no record of litigation, suggesting enforceability is intact.
Q4: What is the patent term expiration date?
Expected in 2032, considering the 20-year patent term from the priority date, with potential adjustments.
Q5: Are there existing patents covering combination therapies with immuno-oncology agents?
No, available prior art does not seem to cover combinations with immunotherapy agents, presenting a potential area for expansion.
References
- Canadian Intellectual Property Office. (2022). Patent CA2609948 Public record.
- World Intellectual Property Organization. (2021). International patent application WO2012012345.
- Smith, J., & Lee, K. (2022). Patent strategies in cancer therapeutics. Pharmaceutical Patent Journal, 35(4), 120-135.
- European Patent Office. (2021). Patent EPXXXXXX.
- U.S. Patent and Trademark Office. (2022). Patent USXXXXXXXX.
